4 startup projects challenging the status quo of their industries win Venture Kick stage 1
23.11.2018
From new drone technology doubling the flight time or a drug speeding up the adoption of CRISPR gene therapies to a sustainable way to buy shoes and new ultrafast 3D printing, 4 new startup projects entered the Venture Kick program. Meet the innovative startup ideas that have successfully passed stage 1.
 Shany Koren and Michael Hauer of Evictas
|
 |
 Samir Bouabdallah and Alexandre Cherpillod of FlybotiX
|
|
 Catalina Jossen Cardozo of By Maria!
|
|
 Paul Delrot of Tomoprint
|
|
Evictas (University of Basel) - Biotech
Evictas is developing a small molecule drug which enhances the efficiency of CRISPR-Cas9 gene therapies, a technology that holds the potential to treat previously incurable genetic diseases. Despite fast progress in research & development, the CRISPR-Cas9 system still remains inefficient in correcting patient cells. The drug developed by Evictas aims to overcome this hurdle and accelerate the application of gene editing technologies in biotech and the clinics.
FlybotiX (EPFL) - Drones
Drones adoption in industrial inspection has started, but flight time is still a strong limitation. Flybotix aims to double the flight time of compact drones. The unique technology is used as a building block to create a compact collision-tolerant drone, suitable for in-structure and indoor inspection. The technology can be used in virtually any drone applications.
By Maria! (Hochschule Luzern) - E-commerce
By Maria produces and sells high-quality designer shoes which are produced fair and environmentally friendly by freelance shoemakers in emerging economies. The independent shoemakers and designers, facing fierce competition from large-scale manufacturers, selling through By Maria’s shop get a bigger share of the price and can develop their assets, physical and human.
Tomoprint (EPFL) - 3D printing
Tomoprint develops the next generation of ultrafast 3D printers to provide highly comfortable orthoses to patients with hearing loss and life-like surgical models to surgeons. Its technology enables the fabrication of complex patient-tailored devices with elastic materials in a matter of seconds, with the aim of improving patient care and simplifying surgical planning.
Evictas is developing a small molecule drug which enhances the efficiency of CRISPR-Cas9 gene therapies, a technology that holds the potential to treat previously incurable genetic diseases. Despite fast progress in research & development, the CRISPR-Cas9 system still remains inefficient in correcting patient cells. The drug developed by Evictas aims to overcome this hurdle and accelerate the application of gene editing technologies in biotech and the clinics.
FlybotiX (EPFL) - Drones
Drones adoption in industrial inspection has started, but flight time is still a strong limitation. Flybotix aims to double the flight time of compact drones. The unique technology is used as a building block to create a compact collision-tolerant drone, suitable for in-structure and indoor inspection. The technology can be used in virtually any drone applications.
By Maria! (Hochschule Luzern) - E-commerce
By Maria produces and sells high-quality designer shoes which are produced fair and environmentally friendly by freelance shoemakers in emerging economies. The independent shoemakers and designers, facing fierce competition from large-scale manufacturers, selling through By Maria’s shop get a bigger share of the price and can develop their assets, physical and human.
Tomoprint (EPFL) - 3D printing
Tomoprint develops the next generation of ultrafast 3D printers to provide highly comfortable orthoses to patients with hearing loss and life-like surgical models to surgeons. Its technology enables the fabrication of complex patient-tailored devices with elastic materials in a matter of seconds, with the aim of improving patient care and simplifying surgical planning.